Sildenafil Actavis

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
13-11-2023
Karakteristik produk Karakteristik produk (SPC)
13-11-2023

Bahan aktif:

sildenafil

Tersedia dari:

Actavis Group PTC ehf

Kode ATC:

G04BE03

INN (Nama Internasional):

sildenafil

Kelompok Terapi:

Urologicals

Area terapi:

Erectile Dysfunction

Indikasi Terapi:

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Sildenafil Actavis to be effective, sexual stimulation is required.

Ringkasan produk:

Revision: 17

Status otorisasi:

Authorised

Tanggal Otorisasi:

2009-12-10

Selebaran informasi

                                30
B. PACKAGE LEAFLET
31
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SILDENAFIL ACTVIS 25 MG, 50 MG AND 100 MG FILM-COATED TABLETS
SILDENAFIL ACTAVIS 25 MG FILM-COATED TABLETS
SILDENAFIL ACTAVIS 50 MG FILM-COATED TABLETS
SILDENAFIL ACTAVIS 100 MG FILM-COATED TABLETS
sildenafil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or
nurse.This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Sildenafil Actavis is and what it is used for
2.
What you need to know before you take Sildenafil Actavis
3.
How to take Sildenafil Actavis
4.
Possible side effects
5.
How to store Sildenafil Actavis
6.
Contents of the pack and other information
1.
WHAT SILDENAFIL ACTAVIS IS AND WHAT IT IS USED FOR
Sildenafil Actavis contains the active substance sildenafil which
belongs to a group of medicines
called phosphodiesterase type 5 (PDE5) inhibitors. It works by helping
to relax the blood vessels in
your penis, allowing blood to flow into your penis when you get
sexually excited. Sildenafil Actavis
will only help you to get an erection if you are sexually stimulated.
Sildenafil Actavis is a treatment for adult men with erectile
dysfunction, sometimes known as
impotence. This is when a man cannot get, or keep a hard, erect penis
suitable for sexual activity.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE SILDENAFIL ACTAVIS
DO NOT TAKE SILDENAFIL ACTAVIS
-
If you are allergic to sildenafil or any of the other ingredients of
this medicine (listed in section
6).
-
If you are taking medicines called nitrates, as the combination may
lead to a dangerous fall in
your blood pressure
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Sildenafil Actavis 25 mg film-coated tablets
Sildenafil Actavis 50 mg film-coated tablets
Sildenafil Actavis 100 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains sildenafil citrate equivalent to 25, 50 or 100 mg
of sildenafil.
Excipient with known effect
Sildenafil Actavis 25 mg tablets
Each tablet contains 62.38 mg lactose (as monohydrate).
Sildenafil Actavis 50 mg tablets
Each tablet contains 124.76 mg lactose (as monohydrate).
Sildenafil Actavis 100 mg tablets
Each tablet contains 249.52 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Sildenafil Actavis 25 mg film-coated tablets
Sildenafil Actavis 25 mg film-coated tablets are blue elliptical,
biconvex, 10.0 x 5.0 mm and marked
“SL25” on one side.
Sildenafil Actavis 50 mg film-coated tablets
Sildenafil Actavis 50 mg film-coated tablets are blue elliptical,
biconvex, 13.0 x 6.5 mm and marked
“SL50” on one side.
Sildenafil Actavis 100 mg film-coated tablets
Sildenafil Actavis 100 mg film-coated tablets are blue elliptical,
biconvex, 17.0 x 8.5 mm and marked
“SL100” on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Sildenafil Actavis is indicated in adult men with erectile
dysfunction, which is the inability to achieve
or maintain a penile erection sufficient for satisfactory sexual
performance.
In order for Sildenafil Actavis to be effective, sexual stimulation is
required.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Use in adults _
The recommended dose is 50 mg taken as needed approximately one hour
before sexual activity.
3
Based on efficacy and tolerability, the dose may be increased to 100
mg or decreased to 25 mg. The
maximum recommended dose is 100 mg. The maximum recommended dosing
frequency is once per
day. If Sildenafil Actavis is taken with food, the onset of activity
may be delayed compared to the
fasted state (see section 5.2)
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 13-11-2023
Karakteristik produk Karakteristik produk Bulgar 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Bulgar 11-05-2015
Selebaran informasi Selebaran informasi Spanyol 13-11-2023
Karakteristik produk Karakteristik produk Spanyol 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Spanyol 11-05-2015
Selebaran informasi Selebaran informasi Cheska 13-11-2023
Karakteristik produk Karakteristik produk Cheska 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Cheska 11-05-2015
Selebaran informasi Selebaran informasi Dansk 13-11-2023
Karakteristik produk Karakteristik produk Dansk 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Dansk 11-05-2015
Selebaran informasi Selebaran informasi Jerman 13-11-2023
Karakteristik produk Karakteristik produk Jerman 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Jerman 11-05-2015
Selebaran informasi Selebaran informasi Esti 13-11-2023
Karakteristik produk Karakteristik produk Esti 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Esti 11-05-2015
Selebaran informasi Selebaran informasi Yunani 13-11-2023
Karakteristik produk Karakteristik produk Yunani 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Yunani 11-05-2015
Selebaran informasi Selebaran informasi Prancis 13-11-2023
Karakteristik produk Karakteristik produk Prancis 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Prancis 11-05-2015
Selebaran informasi Selebaran informasi Italia 13-11-2023
Karakteristik produk Karakteristik produk Italia 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Italia 11-05-2015
Selebaran informasi Selebaran informasi Latvi 13-11-2023
Karakteristik produk Karakteristik produk Latvi 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Latvi 11-05-2015
Selebaran informasi Selebaran informasi Lituavi 13-11-2023
Karakteristik produk Karakteristik produk Lituavi 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Lituavi 11-05-2015
Selebaran informasi Selebaran informasi Hungaria 13-11-2023
Karakteristik produk Karakteristik produk Hungaria 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Hungaria 11-05-2015
Selebaran informasi Selebaran informasi Malta 13-11-2023
Karakteristik produk Karakteristik produk Malta 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Malta 11-05-2015
Selebaran informasi Selebaran informasi Belanda 13-11-2023
Karakteristik produk Karakteristik produk Belanda 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Belanda 11-05-2015
Selebaran informasi Selebaran informasi Polski 13-11-2023
Karakteristik produk Karakteristik produk Polski 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Polski 11-05-2015
Selebaran informasi Selebaran informasi Portugis 13-11-2023
Karakteristik produk Karakteristik produk Portugis 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Portugis 11-05-2015
Selebaran informasi Selebaran informasi Rumania 13-11-2023
Karakteristik produk Karakteristik produk Rumania 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Rumania 11-05-2015
Selebaran informasi Selebaran informasi Slovak 13-11-2023
Karakteristik produk Karakteristik produk Slovak 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Slovak 11-05-2015
Selebaran informasi Selebaran informasi Sloven 13-11-2023
Karakteristik produk Karakteristik produk Sloven 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Sloven 11-05-2015
Selebaran informasi Selebaran informasi Suomi 13-11-2023
Karakteristik produk Karakteristik produk Suomi 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Suomi 11-05-2015
Selebaran informasi Selebaran informasi Swedia 13-11-2023
Karakteristik produk Karakteristik produk Swedia 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Swedia 11-05-2015
Selebaran informasi Selebaran informasi Norwegia 13-11-2023
Karakteristik produk Karakteristik produk Norwegia 13-11-2023
Selebaran informasi Selebaran informasi Islandia 13-11-2023
Karakteristik produk Karakteristik produk Islandia 13-11-2023
Selebaran informasi Selebaran informasi Kroasia 13-11-2023
Karakteristik produk Karakteristik produk Kroasia 13-11-2023
Laporan Penilaian publik Laporan Penilaian publik Kroasia 11-05-2015

Peringatan pencarian terkait dengan produk ini